Abstract: The invention relates to a phosphor with garnet structure and a light-emitting device comprising the phosphor, wherein the phosphor includes the following components in percentage by weight: 38.47-45.19% of Y element, 9.49-22.09% of Al element, 2.06-24.31% of Ga element, 27.3-32.04% of O element, 0.43-1.46% of Ce element. In the phosphor particles, the shortest distance from the surface of one side of the particle to the surface of the opposite side through the centroid of the particle is defined as R, the longest distance is R1, and 5 ?m?R?40 ?m; any distance from the particle surface to the centroid is r, and 0<r<½R; and the space with the distance from the particle surface to the centroid direction being less than or equal to r is defined as rinner.

Abstract: Systems, devices, and methods for performing coordinated clear channel assessments (CCAs) in a shared radiofrequency band are provided. In one aspect, a method of wireless communication performed by a first wireless communication device includes: receiving a control signal indicating a CCA trigger associated with the first wireless communication device and a second wireless communication device; performing, based on the CCA trigger, a CCA; transmitting, to the second wireless communication device based on the CCA, a first CCA success signal; receiving, from the second wireless communication device, a second CCA success signal; initiating, based on the first CCA success signal and the second CCA success signal, a channel occupancy time (COT); and amplifying and forwarding a communication in the COT.

Abstract: A user equipment may be configured to perform active interference cancellation for random-access channel. In some aspects, the user equipment may receive, from a base station, physical layer random-access channel (PRACH) configuration information including one or more active interference cancellation (AIC) parameters for applying AIC to a PRACH message to the base station. Further, the user equipment may transmit, to the base station, the PRACH message with one or more AIC subcarriers based on the one or more AIC parameters.

Abstract: Disclosed are a method and apparatus for sharing information. A particular embodiment of the method comprises: in response to detecting that a user selects article information from a preset candidate item information set, adding the selected article information to a target article information set; detecting whether the user executes a sharing operation with regard to the target article information set; and in response to detecting that the user has executed the sharing operation with regard to the target article information set, sending the target article information set to an object indicated by the sharing operation. According to the embodiment, the flexibility of information sharing is improved.

Abstract: Systems and method for configuring and providing discontinuous reception (DRX) operations in sidelink (SL) mode 1 and mode 2 are disclosed. A first user equipment (UE) may operate in DRX communications with a second UE over a SL while concurrently maintaining DRX communications with a base station. In some embodiments, DRX operations may include the first UE monitoring for either one or both of transmissions in a downlink from a base station and in the SL from the second UE during an active period of a DRX cycle of the DRX configuration. In embodiments, the UE may extend the active period associated with the DRX cycle when control information from either the base station or the second UE is received. Other aspects and features are also claimed and described.

Abstract: A method of wireless communication, by a first sidelink user equipment (UE), includes periodically receiving a set of sidelink beam failure detection reference signals (RSs) from a second sidelink UE. The method includes incrementing a beam failure detection (BFD) counter in response to one or more reference signals of the set of sidelink beam failure detection RSs having a received signal strength below a threshold. The first sidelink UE starts a beam failure detection timer in response to the reference signal(s) of the set of sidelink beam failure detection reference signals having the received signal strength below the threshold. Another method by a sidelink UE may periodically transmit a set of sidelink BFD RSs to another sidelink UE. The set of sidelink BFD RSs comprise one or more sidelink receive RSs. The sidelink UE configures the other sidelink UE with the sidelink receive BFD RSs.

Abstract: Aspects of the disclosure provide techniques for waveform indication for physical uplink control channel (PUCCH) transmissions. A network entity may provide an indication of a waveform type, such as CP-OFDM, DFT-s-OFDM, or other suitable waveform type, for a PUCCH format to a user equipment (UE). The UE may then communicate a PUCCH with the network entity using the waveform type for the PUCCH format.

Abstract: A method of wireless communication by a first sidelink user equipment (UE) transmits a sidelink (SL) beam failure recovery (BFR) message to a communications node, indicating a new candidate beam and an identifier (ID) of a second sidelink UE. The method also receives an acknowledgment of the SL BFR message. A communications node receives a sidelink beam failure recovery message from a first sidelink user equipment, indicating a new candidate beam and an ID of a second sidelink UE. The method also transmits information identifying the new candidate beam and the ID to the second sidelink UE. Another method by a first sidelink user equipment receives a sidelink beam failure recovery message from a base station, indicating a new candidate beam and an ID of a second sidelink UE. The method changes a beam used to communicate with the second sidelink UE in response to receiving the BFR message.

Abstract: The present invention relates to methods and compositions for treating a subject with a condition selected from: i) an on-going cytokine storm, ii) acute respiratory distress syndrome (ARDS), and/or iii) acute lung injury (ALI), using a composition comprising ?-glucocerebrosidase, or a vector encoding ?-glucocerebrosidase. In certain embodiments, the condition is caused by COVID-19 virus infection or other viral infection.

Abstract: Provided herein are compositions, systems, kits, and methods for treating IL-17a related diseases and conditions using an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.

Abstract: Disclosed by the present disclosure are a method and apparatus for displaying product comment information, an electronic device and a storage medium.

Abstract: Provided herein non-human transgenic animals comprising a genome that: i) under-expresses, or is inducible to under-express, Hu Antigen R (HuR) in at least some neurons of said transgenic animal; ii) does not express HuR, or is inducible to not express HuR, in at least some neurons of said transgenic animal; or iii) does not express functional HuR, or is inducible to not express functional HuR in at least some neurons of said transgenic animal, as well as methods of screening drugs and therapies (e.g., useful in treating ALS) using such animals.

Abstract: An azazinoindazole derivative represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, a prodrug thereof, a solvate thereof or a hydrate thereof are presented. The described compound may be used as a 5-HT3 receptor modulator. Experiments have proven that the compound of the preparation example has a strong affinity to 5-HT3 receptors, and has high activity as a modulator of 5-HT3 receptors. The compound may be used to prepare a drug for treating irritable bowel syndrome, nausea, vomiting, gastroenteritis, gastric dysfunction, diarrhea, pain, carcinoid syndrome, drug addiction and other diseases.

Abstract: A method includes receiving, by a first node on a first port of the first node, a first packet from a second node; and when the first packet carries a first flag, avoid selecting, by the first node and when selecting a clock source, a clock source corresponding to the first port, where the first flag indicates that time synchronization of the second node is uncertain.

Abstract: Provided is a solar tile structure, and the solar tile structure includes a solar cell module and a tile. The tile has a first side surface and a second side surface arranged oppositely in a thickness direction of the tile, the first side surface is provided with an embedding groove, and the solar cell module is embedded in the embedding groove. The tile is provided with a disassembly hole, and the disassembly hole is configured to enable the solar cell module to be detached from the embedding groove.

Abstract: Provided herein are compositions, systems, kits, and methods for treating IL-17a related diseases and conditions using an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.

Abstract: Provided herein are compositions, systems, and methods for detecting and treating IL-17 and/or IL-13 related conditions, such as asthma, autoimmune diseases, and cancer. In some embodiments, methods, compositions, and systems are provided for detecting elevated protein or RNA levels of IL-17 (and/or IL-13) and a second marker selected from: SAA, LCN2, and YKL-40, and treating the subject with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor. In other embodiments, methods, compositions, and systems are provided for detecting a biomarker in a sample from a subject that has been treated with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor, where the biomarker is SAA, LCN2, or YKL-40, and where at least one action is performed, such as identifying elevated levels of the biomarker in the biological sample and treating the subject with an IL-17 (or IL-13) inhibitor and/or IL-17 (or IL-13) receptor inhibitor.

Abstract: The present invention relates to methods and compositions for treating a subject with a condition selected from: i) an on-going cytokine storm, ii) acute respiratory distress syndrome (ARDS), and/or iii) acute lung injury (ALI), using a composition comprising ?-glucocerebrosidase, or a vector encoding ?-glucocerebrosidase. In certain embodiments, the condition is caused by COVID-19 virus infection or other viral infection.

Abstract: The present invention describes a method of treating a steroid-resistant disease or condition such as severe asthma in a subject by administering a therapeutically effective amount of an anthocyanin and a corticosteroid to a subject in need thereof.